 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...467468469470471472473474475476477...522523» |
- || cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg.
Trial primary completion date, Metastases: NeoSAMBA: Neoadjuvant: Does the Sequence of Anthracycline and Taxane Matters: Before or After? (clinicaltrials.gov) - Nov 18, 2017
P2, N=112, Active, not recruiting, Sponsor: Instituto Nacional de Cancer, Brazil
Trial primary completion date: Sep 2016 --> Apr 2018
- | Phase classification: DA-EPOCH-R: Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies (clinicaltrials.gov) - Nov 17, 2017
P1, N=4, Completed, Sponsor: Baylor College of Medicine
Trial primary completion date: Sep 2016 --> Apr 2018 Phase classification: P=N/A --> P1
- | Biomarker, Enrollment closed: Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A (clinicaltrials.gov) - Nov 17, 2017
P2, N=40, Active, not recruiting, Sponsor: Baylor College of Medicine
Phase classification: P=N/A --> P1 Recruiting --> Active, not recruiting
- | Trial primary completion date: RETAIN BLADDER: Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN) (clinicaltrials.gov) - Nov 17, 2017
P2, N=38, Recruiting, Sponsor: Fox Chase Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2018 --> Apr 2020
- |||| Tirazone (tirapazamine) / Teclison, SRI International
Enrollment open: TATE Versus TACE in Intermediate Stage HCC (clinicaltrials.gov) - Nov 17, 2017
P2, N=134, Recruiting, Sponsor: Teclison Ltd.
Trial primary completion date: Apr 2018 --> Apr 2020 Not yet recruiting --> Recruiting
- | doxorubicin hydrochloride / Generic mfg.
Enrollment open: Myocardial Perfusion and Fibrosis in Cancer Survivors (clinicaltrials.gov) - Nov 17, 2017
P=N/A, N=16, Recruiting, Sponsor: Wake Forest University Health Sciences
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer, Opdivo (nivolumab) / BMS
Trial initiation date, PD(L)-1 Biomarker: ACCRU-LY-1601: Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma (clinicaltrials.gov) - Nov 17, 2017
P2, N=85, Not yet recruiting, Sponsor: Academic and Community Cancer Research United
Not yet recruiting --> Recruiting Initiation date: Aug 2017 --> Feb 2018
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open, Trial primary completion date: Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov) - Nov 17, 2017
P1, N=54, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Aug 2017 --> Feb 2018 Not yet recruiting --> Recruiting | Trial primary completion date: May 2019 --> Sep 2020
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P1/2 trial: Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs (clinicaltrials.gov) - Nov 17, 2017
P1/2, N=30, Recruiting, Sponsor: Chinese PLA General Hospital
- | ifosfamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Journal: SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors. (Pubmed Central) - Nov 16, 2017
This trial was not powered to detect differences in response rates between NF1 and sporadic MPNST. While the OR rate was lower in NF1 compared to sporadic MPNST, qualitative responses were similar, and disease stabilization was achieved in most patients.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Pharmacokinetic-pharmacodynamic modeling of acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer. (Pubmed Central) - Nov 16, 2017
Future studies are warranted to examine the relationship between this acute response and subsequent heart failure. Should such a relationship be established, this model could provide useful information on patients' susceptibility to doxorubicin-induced long-term cardiotoxicity.
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial primary completion date: R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B (clinicaltrials.gov) - Nov 14, 2017
P3, N=648, Active, not recruiting, Sponsor: Ruijin Hospital
Should such a relationship be established, this model could provide useful information on patients' susceptibility to doxorubicin-induced long-term cardiotoxicity. Trial primary completion date: Apr 2017 --> Dec 2017
- | Pinorubin (pirarubicin) / Sanofi
Enrollment closed, Trial primary completion date: CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma (clinicaltrials.gov) - Nov 14, 2017
P4, N=200, Active, not recruiting, Sponsor: Ruijin Hospital
Trial primary completion date: Apr 2017 --> Dec 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Sep 2018
- Ninlaro (ixazomib) / Takeda
Trial primary completion date: Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults (clinicaltrials.gov) - Nov 14, 2017
P1, N=28, Recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Sep 2018 Trial primary completion date: Oct 2017 --> Mar 2018
- ||||| Aliqopa (copanlisib) / Bayer
Enrollment change, Combination therapy: CHRONOS-4: Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) (clinicaltrials.gov) - Nov 14, 2017
P3, N=520, Recruiting, Sponsor: Bayer
Trial primary completion date: Oct 2017 --> Mar 2018 N=676 --> 520
- | Epidaza (chidamide) / Chipscreen, Meiji Seika, Eisai, HUYA Bioscience, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial primary completion date, Combination therapy: Chidamide Plus R-CHOP in Elderly DLBCL (clinicaltrials.gov) - Nov 14, 2017
P2, N=49, Recruiting, Sponsor: Ruijin Hospital
N=676 --> 520 Trial primary completion date: Oct 2017 --> Oct 2018
- Promacta (eltrombopag) / Novartis
Enrollment change: Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide (clinicaltrials.gov) - Nov 13, 2017
P1, N=18, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Oct 2017 --> Oct 2018 N=48 --> 18
- | Votrient (pazopanib) / Novartis
Enrollment change, Trial initiation date, Trial termination, Trial primary completion date: Pazopanib Maintenance Phase II (clinicaltrials.gov) - Nov 13, 2017
P2, N=1, Terminated, Sponsor: Ludwig-Maximilians - University of Munich
N=48 --> 18 N=150 --> 1 | Initiation date: Dec 2014 --> Jun 2015 | Recruiting --> Terminated | Trial primary completion date: Jun 2017 --> Jul 2016; poor recruitment
- | cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
New trial: Neurovascular Changes Induced by Chemotherapy (clinicaltrials.gov) - Nov 13, 2017
P=N/A, N=16, Completed, Sponsor: University of Sao Paulo General Hospital
- | Tecentriq (atezolizumab) / Roche
New P2 trial: Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer (clinicaltrials.gov) - Nov 13, 2017
P2, N=48, Recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
- | doxorubicin hydrochloride / Generic mfg.
Retrospective data, Journal: Segmental Yttrium-90 Radioembolization versus Segmental Chemoembolization for Localized Hepatocellular Carcinoma: Results of a Single-Center, Retrospective, Propensity Score-Matched Study. (Pubmed Central) - Nov 10, 2017
Segmental radioembolization demonstrates higher complete response rates and local tumor control compared with segmental chemoembolization for HCC, with similar toxicity profiles. Superior progression-free survival was achieved.
- | Journal: Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma. (Pubmed Central) - Nov 10, 2017
Superior progression-free survival was achieved. From a Belgian payer perspective, PP with pegfilgrastim appears cost effective compared to other prophylaxis strategies in patients with stage II breast cancer or NHL at a €30,000/QALY threshold.
- | Journal: Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy. (Pubmed Central) - Nov 10, 2017
The key risk factors for the development of PRES identified in our study included hypertension, fluid imbalance, electrolyte abnormalities, baseline organ dysfunction, a high tumor burden, and the presence of pre-existing CNS insults during chemotherapy, such as CNS infection. Patients with these risk factors appear to have a greater risk of developing PRES and should be monitored closely during treatment.
- | doxorubicin hydrochloride / Generic mfg.
Review, Clinical Trial,Phase I, Journal: A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study. (Pubmed Central) - Nov 10, 2017
Patients with these risk factors appear to have a greater risk of developing PRES and should be monitored closely during treatment. GEN-1 in combination with PLD has encouraging clinical benefit and biological activity in recurrent or persistent EOC and warrants further investigation with escalating doses of GEN-1.
- | Onzeald (etirinotecan pegol) / Nektar Therap
Clinical Trial,Phase I, Clinical Trial,Phase II, Journal: A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer. (Pubmed Central) - Nov 10, 2017
This study confirms the activity and safety of single-agent EP in patients with PROC, including patients who received prior PLD. Further evaluation earlier in the disease course and in combination is warranted.
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions. (Pubmed Central) - Nov 9, 2017
Among advanced-stage patients with bulky disease (n = 35), consolidative RT to sites of bulky disease may have improved local control (3-year local control, 100% vs 60.3%, P = .160). Among patients aged 80 years or older who have with ES DLBCL, 3 to 4 cycles of chemotherapy followed by RT is at least equivalent in efficacy to chemotherapy alone and is associated with lower levels of toxicity, which suggests that it may be a better choice for therapy when trying to balance treatment efficacy and tolerability.
- || Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment closed, Combination therapy: A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Nov 9, 2017
P1, N=92, Active, not recruiting, Sponsor: Hoffmann-La Roche
Among patients aged 80 years or older who have with ES DLBCL, 3 to 4 cycles of chemotherapy followed by RT is at least equivalent in efficacy to chemotherapy alone and is associated with lower levels of toxicity, which suggests that it may be a better choice for therapy when trying to balance treatment efficacy and tolerability. Recruiting --> Active, not recruiting
- | Trial initiation date: Vaccination of Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Nov 9, 2017
P2, N=102, Not yet recruiting, Sponsor: University of Arkansas
Recruiting --> Active, not recruiting Initiation date: Oct 2017 --> Oct 2018
- | doxorubicin hydrochloride / Generic mfg.
New P3 trial, Metastases: SBRT or TACE for Advanced HCC (clinicaltrials.gov) - Nov 9, 2017
P3, N=180, Recruiting, Sponsor: University of Aarhus
- | Trial primary completion date: International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry (clinicaltrials.gov) - Nov 8, 2017
P=N/A, N=125, Recruiting, Sponsor: Children's Hospitals and Clinics of Minnesota
Initiation date: Oct 2017 --> Oct 2018 Trial primary completion date: Sep 2016 --> Dec 2019
- | Adcetris (brentuximab vedotin) / Seagen, Takeda
Trial primary completion date: Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma (clinicaltrials.gov) - Nov 8, 2017
P2, N=70, Recruiting, Sponsor: University of Cologne
Trial primary completion date: Sep 2016 --> Dec 2019 Trial primary completion date: Oct 2017 --> May 2018
- | paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Journal: Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. (Pubmed Central) - Nov 8, 2017
There was no significant rise in G-MDSC from draw 1 to 3 in African American patients, and at draw 3 G-MDSC levels were significantly lower in African Americans versus Caucasians (p < 0.05). It was concluded that G-MDSC% increased during doxorubicin and cyclophosphamide therapy, but did not significantly differ between patients based on pathologic complete response.
- | Enrollment closed: ASTER 70s: Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment (clinicaltrials.gov) - Nov 7, 2017
P3, N=2000, Active, not recruiting, Sponsor: UNICANCER
It was concluded that G-MDSC% increased during doxorubicin and cyclophosphamide therapy, but did not significantly differ between patients based on pathologic complete response. Recruiting --> Active, not recruiting
- | Genasense (oblimersen) / Genta
Trial completion, Combination therapy, Metastases: Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) (clinicaltrials.gov) - Nov 7, 2017
P2, N=27, Completed, Sponsor: University Health Network, Toronto
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Trial primary completion date, FDG PET: Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant (clinicaltrials.gov) - Nov 7, 2017
P2, N=59, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Feb 2009 --> Sep 2007
- | Kepivance (palifermin) / SOBI, Amgen
Trial primary completion date: Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (clinicaltrials.gov) - Nov 6, 2017
P1/2, N=50, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2009 --> Sep 2007 Trial primary completion date: Jan 2019 --> Jan 2023
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer (clinicaltrials.gov) - Nov 6, 2017
P2, N=75, Not yet recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
- | Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial, PD(L)-1 Biomarker: NCI-2017-01718: Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma (clinicaltrials.gov) - Nov 6, 2017
P2, N=30, Not yet recruiting, Sponsor: University of Washington
- | zidovudine / Generic mfg.
Journal: Adult T-Cell Leukemia/Lymphoma: Rarely Encountered in the United States. (Pubmed Central) - Nov 5, 2017
We present 10 patients with acute and lymphomatous subtypes of ATLL treated with distinct induction regimens, including CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine [Oncovin], prednisone or prednisolone), interferon/zidovudine, and VCAP-AMP-VECP (vincristine, cyclophosphamide, doxorubicin, prednisone; doxorubicin, ranimustine, prednisone; vindesine, etoposide, carboplatin, prednisone)...Three patients underwent consolidation with allogeneic stem cell transplantation (ASCT) in the first CR. The median overall survival was 51 months for the entire group and 84 months for the patients who had undergone ASCT versus 34 months for the non-ASCT patients.
- | Ziextenzo (pegfilgrastim biosimilar) / Novartis, Zarzio (filgrastim biosimilar) / Novartis, Neulasta (pegfilgrastim) / Amgen, Kyowa Hakko Kirin, Roche
Journal: A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial. (Pubmed Central) - Nov 3, 2017
Biosimilar pegfilgrastim (LA-EP2006) may benefit oncology patients by offering increased access to biological treatments that may improve clinical outcomes. This means that patients could potentially be treated prophylactically with biologics rather than only after complications have occurred.
- | denintuzumab mafodotin (SGN-CD19A) / Pfizer
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy: Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma (clinicaltrials.gov) - Nov 1, 2017
P2, N=24, Active, not recruiting, Sponsor: Seattle Genetics, Inc.
This means that patients could potentially be treated prophylactically with biologics rather than only after complications have occurred. Recruiting --> Active, not recruiting | N=160 --> 24 | Trial primary completion date: Sep 2019 --> Jan 2018
- | anti-HER2 antibody conjugated with pegylated liposomal doxorubicin (MM-302) / Merrimack
Journal: HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. (Pubmed Central) - Nov 1, 2017
P2/3
Recruiting --> Active, not recruiting | N=160 --> 24 | Trial primary completion date: Sep 2019 --> Jan 2018 The HERMIONE study will evaluate the efficacy and safety of MM-302 plus trastuzumab in patients with refractory HER2-positive advanced/metastatic breast cancer for whom there are no standard of care therapies with a proven survival advantage.
- | Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Biomarker, Clinical Trial,Phase I, Clinical Trial,Phase II, Clinical Trial,Phase III, Journal: Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. (Pubmed Central) - Nov 1, 2017
AEs reported with G were consistent with the known safety profile. Biomarker analyses may help define a future role for G in DLBCL.
- | dacarbazine / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Journal: Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone? (Pubmed Central) - Nov 1, 2017
Risk factors for recurrence in this subgroup included a small reduction in tumour size and a 'bounce' in ≥1 PET-CT parameter (reduction then rise from interim to final scan). Thus, a positive eoc-PET-CT is associated with inferior FFP; however, appropriately selected patients can be cured with RT alone.
- | bortezomib / Generic mfg., Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical Trial,Phase I, Clinical Trial,Phase II, Journal: Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. (Pubmed Central) - Nov 1, 2017
In the safety population (100 R-CHOP and 101 VR-CHOP patients), grade ≥ 3 adverse events included neutropenia (53% v 49%), thrombocytopenia (13% v 29%), anemia (7% v 15%), leukopenia (26% v 25%), and neuropathy (1% v 5%). Conclusion Outcomes for newly diagnosed, prospectively enrolled patients with non-GCB DLBCL were more favorable than expected with R-CHOP and were not significantly improved by adding bortezomib.
- | Journal: Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group. (Pubmed Central) - Nov 1, 2017
Responders to VI received two additional cycles of VI intermixed with six cycles of cisplatin/fluorouracil/vincristine/doxorubicin (C5VD), and nonresponders received six cycles of C5VD alone...Lesions that fail to meet RECIST size criteria (ie, those < 10 mm) at diagnosis may contain viable tumor, whereas residual lesions at the end of therapy may constitute eradicated tumor/scar tissue. Patients may benefit from risk stratification on the basis of the burden of lung metastatic disease at diagnosis.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion. (Pubmed Central) - Oct 31, 2017
Patients may benefit from risk stratification on the basis of the burden of lung metastatic disease at diagnosis. Doxorubicin cardiotoxicity can be limited by administering doxorubicin as a continuous infusion, allowing higher cumulative dosing to maximize efficacy.
- | Enrollment change: Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma (clinicaltrials.gov) - Oct 31, 2017
P2, N=100, Recruiting, Sponsor: St. Jude Children's Research Hospital
Doxorubicin cardiotoxicity can be limited by administering doxorubicin as a continuous infusion, allowing higher cumulative dosing to maximize efficacy. N=80 --> 100
- | Trial primary completion date: NeoSTOP: Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer (clinicaltrials.gov) - Oct 30, 2017
P2, N=100, Recruiting, Sponsor: Priyanka Sharma
N=80 --> 100 Trial primary completion date: Jul 2017 --> Jul 2018
- | Emcyt (estramustine) / Pfizer, Nippon Shinyaku, Firmagon (degarelix) / Astellas, Ferring
Enrollment change, Trial termination, Trial primary completion date, Metastases: Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer (clinicaltrials.gov) - Oct 30, 2017
P2, N=23, Terminated, Sponsor: The University of Texas Health Science Center, Houston
Trial primary completion date: Jul 2017 --> Jul 2018 N=224 --> 23 | Recruiting --> Terminated | Trial primary completion date: Nov 2020 --> Sep 2017; Slow accrual; resource re-allocation